Alcohol Use Disorder
Behavioral therapies, naltrexone, acamprosate, AUDIT screening.
Alcohol use disorder remains the most prevalent substance use disorder yet the most undertreated, with fewer than ten percent of patients receiving evidence-based pharmacotherapy. The track will cover the established triad — naltrexone (oral and extended-release), acamprosate, and disulfiram — alongside off-label evidence for topiramate, gabapentin, and baclofen. A dedicated session will examine the rapidly accumulating signal that GLP-1 receptor agonists (semaglutide, tirzepatide) reduce alcohol craving and consumption, including readouts from semaglutide AUD trials. Behavioral content covers CBT, MET, the COMBINE study legacy, and integration of AUDIT-C screening into primary care.
- GLP-1 receptor agonists for AUD: semaglutide and tirzepatide trial data
- Naltrexone (oral, extended-release) and the Sinclair method
- Acamprosate, disulfiram, and supervised dosing models
- Off-label pharmacotherapy: topiramate, gabapentin, baclofen evidence
- AUDIT-C screening and SBIRT in primary care workflows
- Alcohol-associated liver disease and early transplant referral
- Managed alcohol programs and harm-reduction approaches to AUD